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More than a decade ago, the expression of MHCII genes
was known to require several protein complexes (re-
BLS is an autosomal recessive disease, where patients viewed in Reith and Mach, 2001; Ting and Trowsdale,
fail to express MHCII determinants on their immune cells 2002), but their specific subunits had not been identified.
(reviewed in Reith and Mach, 2001; Ting and Trowsdale, The earliest efforts to characterize proteins that bind
2002). As a consequence, thymic education and periph- conserved upstream sequences (CUS) in their compact
eral T cell help are compromised. All these manifesta- promoters (Figure 1) employed in vitro assays that iden-
tions can be explained by the absence of antigen pro- tified numerous DNA-protein interactions. However, the
cessing and presentation (APP) via MHCII molecules “acid test” for the relevance of these complexes, individ-
(reviewed in Klein et al., 1993; Villard et al., 2001). Be- ual subunits of which were still unknown, was never
cause hematopoiesis is not affected, BLS patients have met; i.e., they were unaltered in cell lines derived from
normal numbers of circulating B and T cells, but the BLS patients. Antisense experiments, which reduced
CD4 T cell counts are reduced. Nevertheless, they are the expression of the X1 box binding protein RFX1 or
unable to mount immune responses to foreign antigens, the X2 box binding protein XBP-1 had modest effects
as manifested by absent delayed type hypersensitivity on MHCII transcription (Reith et al., 1990). However,
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and/or to the lack of T cell help. Most patients die in
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Figure 1. cis-Acting Sequences and trans-Acting Factors on MHCII Promoters
Conserved upstream sequences (CUS) in the distal promoter contain S, X, and Y boxes. The X box is subdivided further into X1 and X2 boxes.
Whereas the spacing between S and X boxes is invariant, X and Y boxes can be moved by single helical turns. In the DRA gene, the octamer
binding site (OBS) and Initiator form the core or proximal promoter. RFX, which contains RFXANK/B, RFXAP, and RFX5, binds S and X1
boxes. X2 box binding protein (X2BP) binds the X2 box. NF-Y, which contains NF-YA, NF-YB, and NF-YC, binds the Y box. Octamer binding
proteins bind OBS. In turn, they recruit the B cell octamer binding protein 1/Octamer binding factor 1/Oct coactivator from B cells (Bob1/
OBF-1/OCAB, here OCAB). The initiator binds general transcription factors and TAFs. It positions RNA polymerase II (RNAPII) correctly for
the initation of transcription. CIITA is recruited to the MHCII enhanceosome, which consists of RFX, X2BP, NF-Y on CUS. It binds histone
acetyl transferases (HATs, CBP/p300, and P-CAF) and SWI/SNF complexes (via BRG-1) that remodel chromatin, GTFs, OCAB, and TAFs that
recruit RNAPII, and P-TEFb that phosphorylates its C-terminal domain (CTD) and facilitates the elongation of MHCII transcription. Steps in
the transcription process are given above the drawing.
ment (Reimold et al., 2000) or impaired plasma cell differ- promoters, X2BP and other transcriptional activators
can be isotype specific (reviewed in Reith and Mach,entiation (Reimold et al., 2001), respectively.
Eventually, efforts to purify the correct CUS binding 2001; Ting and Trowsdale, 2002). RFX5, which contains
a winged-helix DNA binding domain (DBD) (Gajiwala etcomplexes were successful. However, it required the
genetic identification of RFX5, which rescued the ex- al., 2000), forms oligomers (Jabrane-Ferrat et al., 2002)
and binds preassembled RFXANK/B and RFXAP (Nek-pression of MHCII determinants in CG C cells (Steimle et
al., 1995). Although CIITA was also cloned using genetic rep et al., 2000) (Figure 2). RFX and NF-Y then form the
enhanceosome (Figure 2). The assembly begins off DNAcomplementation in CG A cells (Steimle et al., 1993),
RFXANK/B (Masternak et al., 1998; Nagarajan et al., but is strengthened by DNA-protein interactions. Indi-
vidual DBDs contact CUS on the same side of the double1999), and RFXAP (Durand et al., 1997) could then be
isolated biochemically. To date, these three subunits of helix, which explains the constrained topology between
S, X, and Y boxes (Figure 2). By selecting against andRFX and CIITA not only account for all CGs of BLS but
represent the only gene-specific regulatory factors for for RFX1 and RFX5, respectively, NF-Y specifies and
stabilizes the final enhanceosome (Fontes et al., 1997).MHCII promoters.
Assembly of MHCII Enhanceosome CIITA is a coactivator that does not bind DNA but in-
teracts with this transcriptional platform via multipleand Transcriptosome
Essential complexes for MHCII transcription include the subunits of RFX and NF-Y (Ting and Trowsdale, 2002).
Together, they form the transcriptosome (Ting andnuclear factor Y (NF-Y), which consists of NF-YA, NF-
YB, and NF-YC that bind the Y box, oligomers of RFX Trowsdale, 2002) (Figure 2). The posttranslational modi-
fication of CIITA by phosphorylation leads to its oligo-that bind X1 and S boxes, X2 box binding proteins
(X2BP: CREB or activated protein 1, AP-1) that bind the merization, accumulation, and increased activity on
MHCII promoters (Figure 2) (Tosi et al., 2002). OtherX2 box, and CIITA (Figures 1 and 2) (reviewed in Reith
and Mach, 2001; Ting and Trowsdale, 2002). S, X1, X2, modifications include acetylation and ubiquitylation,
which could modulate its retention in the nucleus andand Y boxes are contained in CUS. They are present in
the promoters of structural ( and  chains of DR, DO, stability, respectively. X2BP contributes to the formation
of the enhanceosome (Moreno et al., 1999). Thus, it isDP, and DQ isotypes) as well as MHCII-associated DMA,
DMB, and invariant chain (Ii) genes. Proximal MHCII not surprising that the absence of any subunit of RFX
leads to unoccupied, bare MHCII promoters in in vivopromoters lack a typical TATA box but contain initiator
sequences (Inr) (reviewed in Reith and Mach, 2001; Ting footprinting studies (CG B, C, and D). In sharp contrast,
they are occupied in CG A, which lacks CIITA (Kara andand Trowsdale, 2002) (Figure 1).
While RFX and NF-Y are indispensable for all MHCII Glimcher, 1991).
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Figure 2. The Assembly of the MHCII En-
hanceosome and Transcriptosome
Via its ankyrin repeats, RFXANK/B binds
RFXAP and nucleates the RFX complex.
RFX5 is recruited to this combinatorial sur-
face and forms oligomers. RFX binds S and
X boxes and NF-Y the Y box. They form the
MHCII enhanceosome, which is strengthened
by X2BP (not presented). CIITA, which is ex-
pressed from four separate and differentially
regulated promoters, is modified posttransla-
tionally (here by phosphorylation), which
leads to its oligomerization and retention on
MHCII promoters. It helps to form the MHCII
transcriptosome, which contains the preiniti-
ation complex (PIC).
CIITA is a transcriptional integrator (Fontes et al., is a powerful method for site-directed binding studies
and better evaluation of BLS. Let us look more closely1999). Chromatin remodeling complexes, basal tran-
scription factors, and proteins involved in the elongation at some of them.
RFXANK/B is mutated in CG B that contains theof transcription bind CIITA (Figure 1). Histone acetylation
and SWI/SNF complexes modulate the chromatin struc- largest number of BLS patients. The severity of BLS can
be correlated with levels of residual MHCII determinantsture at MHCII promoters. Indeed, X2BP, NF-Y, and CIITA
recruit several histone acetyltransferases, and CIITA has on patients’ immune cells. Their levels can be increased
by exogenous CIITA, e.g., in patients FZA and EBA (Na-been reported to possess intrinsic acetyltransferase ac-
tivity (reviewed in Ting and Trowsdale, 2002). Changes garajan et al., 2000). Thus, CIITA stabilizes the existing
enhanceosome and ameliorates the BLS defect. In FZAin acetylation of histones H3 and H4 have also been
correlated with MHCII transcription (Beresford and patient, RFXANK/B carries the point mutation L195P.
Although the corresponding mRNA is expressed at wild-Boss, 2001). By binding the brahma related gene-1
(BRG-1), CIITA also recruits the chromatin remodeling type levels, less than 1% of MHCII determinants are ex-
pressed on the surface of the patient’s cells (NagarajanSWI/SNF complex (Mudhasani and Fontes, 2002). Fur-
thermore, CIITA binds components of the general tran- et al., 2000). Insight into the structure of ankyrin repeats
in RFXANK/B elucidated the mechanism of this mutationscription apparatus, including TFIIB, TFIIH, hTAFII32,
and hTAFII70 and the B cell octamer binding protein (Figure 3) (Nekrep et al., 2001). Furthermore, it led to
alanine mutageneses of exposed variable residues that1/Octamer binding factor 1/Oct coactivator from B cells
(Bob1/OBF-1/OCAB) (reviewed in Reith and Mach, 2001; mapped the interacting surfaces with RFXAP and CIITA.
For example, -hairpin loops in the three N-terminal an-Ting and Trowsdale, 2002). Finally, the recruitment of
P-TEFb leads to the efficient elongation of transcription kyrin repeats and one helix in the third ankyrin groove
are required for the binding between RFXANK/B and(Kanazawa et al., 2000) (Figure 1).
Single Amino Acid Substitutions in Proteins Offer RFXAP, which nucleates RFX. Thus, the mutation L195P
is likely to break the inner helix in the third ankyrin repeatStructural Clues
The MHCII enhanceosome cannot form in the absence and block the formation of the RFX complex (Figure 3).
Several cases of discordant expression of MHCIIof any subunit of RFX, and promoters remain unoccu-
pied in vivo (Masternak et al., 2000). Thus, in a typical genes were described in BLS. Immortalized Clone13 B
cells lack functional CIITA and express DQ but not DRBLS, MHCII genes are not transcribed. However, there
are several exceptions to this rule, and representative or DP isotypes (Douhan et al., 1997), and revertants of
mutant 6.1.6 B cells express only DR and DP isotypespatients fall into one of two broadly defined groups. In
the first, patients’ immune cells express residual surface (Levine and Pious, 1984). Moreover, exogenous CIITA
increased the expression of only the DR isotype on fibro-MHCII determinants. In the second, patients’ cells show
a discordant expression of MHCII genes, where only blasts from patient SSI from CG C (Peijnenburg et al.,
1999). This discordant expression might reflect differentcertain genes are active. Since their immune systems
retain some APP, both groups of patients experience a promoter strengths of the genes in the MHCII locus
(Masternak and Reith, 2002; Nekrep et al., 2002). Indeed,milder course of disease. In this atypical BLS, genes
coding for transcription factors contain single point mu- different binding affinities for different MHCII promoters
were demonstrated for RFX and X2BP (Hasegawa andtations. Mutant proteins retain most of their functional
domains. By modeling these domains based on homolo- Boss, 1991).
Perhaps the most intriguing case of discordant ex-gous modules with known crystal structure, it is possible
to visualize the location of the point mutation that causes pression of MHCII genes was found in twins Ken and
Ker, where only promoters facing the centromere on thethe disease. Therefore, the three-dimensional structure
Immunity
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Figure 3. A Model of Ankyrin Repeats in
RFXANK/B (from Positions 88 to 243)
-hairpin loops and inner helices in ankyrin
repeats mediate the interaction between
RFXANK/B and RFXAP. The critical leucine
at position 195 (red residue) is located in the
first (inner) helix of the third ankyrin repeat
(see arrow). Its mutation to proline in patient
FZA of CG B is likely to break that helix and
destabilize the structure of the ankyrin re-
peats.
short arm of chromosome 6 are expressed (Figure 4) reduced or does not occur at all (Figure 5). The general
picture of the four CGs of BLS is now complete.(Douhan et al., 1996). This finding suggested a chromatin
remodeling defect, possibly in a putative locus organiz- Immunological Lessons
BLS is a relatively rare hereditary SCID that is found ining region. Moreover, because of fusions with cells form
other CGs, Ken and Ker were placed into the fifth CG families with high degree of consanguinity (reviewed in
Klein et al., 1993; Villard et al., 2001; Reith and Mach,(CG E) of BLS. However, they contain a point mutation
in the winged-helix DBD of RFX5 (Figure 5) (Nekrep et 2001). While severe BLS represents complete SCID, in
less severe cases, residual expression of MHCII deter-al., 2002). Indeed, the wild-type RFX5 protein restored
the binding of RFX to DNA, transcription of previously minants on certain immune cells enables some thymic
education and peripheral immune responses. BLS issilent genes and expression of MHCII determinants on
the surface of affected B cells. The crystal structure of often fatal and requires bone marrow transplantation.
Milder forms of this disease require repeated immuno-the DBD of RFX1 (Gajiwala et al., 2000) bound to a
symmetrical X box DNA was used as a matrix for model- globulin injections and rapid treatment of infections. In
them, the function of cytolytic lymphocytes also remainsing the three-dimensional structure of the DBD of RFX5,
which then explained the mechanism of this mutation intact.
Perhaps the most important lesson from BLS is that(Nekrep et al., 2002). Indeed, the arginine at position
149 in RFX5 is one of nine residues that form a direct there are at least four essential, i.e., nonredundant and
interconnected genes that are dedicated solely to triggercontact with DNA (Gajiwala et al., 2000). Its mutation to
glutamine, which is found in Ken and Ker, leads to the APP by the MHCII compartment. Since CIITA is ex-
pressed from up to four distinct promoters only in thymicloss of a positive charge in the DNA binding interface
and the loss of several hydrogen bonds that are required epithelial cells, professional APCs, and mature B cells,
CIITA is the master switch of this process. As RFX isfor DNA-protein interactions (Nekrep et al., 2002). As a
consequence, one major contact point that RFX5 makes found in all cells, it is also the only protein that must be
introduced into somatic cells to render them APCs (Reithwith DNA is lost and binding of RFX to DNA is markedly
Figure 4. The Organization of MHCII Genes
on the Short Arm of the Human Chromosome
6, Direction of Their Transcription, and Active
Promoters in Ken and Ker Cells
Three structural and polymorphic hetero-
dimers are transcribed from promoters that
point in opposite directions (DRA and DRB,
DQA and DQB, DPA and DPB, short black
arrows). Monomorphic DOA and DOB as well
as DMA and DMB heterodimers are also tran-
scribed, but their promoters face the telo-
mere (long black arrows). Genes for  and 
chains are depicted as red and green bars,
respectively. Several DRB, DQ, and DP pseu-
dogenes are also found (gray bars). Orange
bars depict MHCII-unrelated genes. In Ken
and Ker cells, only promoters facing the cen-
tromere are transcribed (red arrows); thus, no
productive MHCII heterodimers form.
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Aebersold, R., Sanchez, J.C., Hochstrasser, D.F., Mach, B., andand Mach, 2001). Caveats include the posttranslational
Reith, W. (1998). Nat. Genet. 20, 273–277.modification of CIITA and the presence of appropriate
Masternak, K., Muhlethaler-Mottet, A., Villard, J., Zufferey, M.,proteases to produce antigenic peptides. This knowl-
Steimle, V., and Reith, W. (2000). Genes Dev. 14, 1156–1166.edge is of importance for the future manipulation of the
Masternak, K., and Reith, W. (2002). EMBO J. 21, 1379–1388.immune response, how it can be increased in immuno-
Moreno, C.S., Beresford, G.W., Louis-Plence, P., Morris, A.C., anddeficiencies and attenuated in autoimmune diseases.
Boss, J.M. (1999). Immunity 10, 143–151.Finally, genetic approaches with wild-type subunits of
Mudhasani, R., and Fontes, J.D. (2002). Mol. Cell. Biol. 22, 5019–RFX and CIITA offer a better alternative to bone marrow
5026.
transplantation for the cure of BLS.
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Figure 5. A Model of the Wild-Type and Mutant Winged-Helix DNA Binding Domains (DBD) from RFX5 On and Off DNA
In the wild-type RFX5 protein, nine residues mediate direct intermolecular contacts to nucleotides of the palindromic X1 box (left panel). In
Ken and Ker, a critical arginine residue at position 149, which forms the interface with DNA, is mutated to glutamine. As a consequence, the
binding of RFX to DNA is markedly reduced or does not occur at all (right panel).
